APR 14, 2017 11:31 AM PDT

New in Immunotherapy: Blocking Cancer Blood Vessels

WRITTEN BY: Kara Marker

Immunotherapy is a method of fighting cancer that revolves around empowering the immune system to reach its full cancer-killing potential. But tumor cells are constantly finding ways to resist and retaliate, so counterattacks are always necessary.

An antibody against ANGPT2 and VEGFA reprograms the tumor blood vessels to facilitate the extravasation of anti-tumoral T cells. Credit: Ella Maru Studio

A growing tumor generates its own system of blood vessels that flood cancer cells with oxygen and nutrients. In addition to providing nourishment, these vessels block the arrival of T cells either naturally sent by the immune system or sent as a result of an immunotherapy to boost T cell activity. Tumors rely on two key proteins to stimulate the growth of their blood vessel network and to keep T cells at bay: VEGFA and ANGPT2.

A new approach designed by experts from the Ecole Polytechnique Federale De Lausanne (EPFL) in Switzerland may be the answer: an antibody called A2V that simultaneously blocks VEGFA and ANGPT2 and metastasis.

"A2V not only regressed most of the tumor blood vessels, but also reversed the aberrant features of those that had remained, making them similar to normal blood vessels and more permissive to the arrival of anti-tumoral T cells,” explained study leader Michele De Palma.

By preventing tumors from reaping the benefits of their blood vessel system, A2V offers a new solution for treating many different types of cancer. However, the EPFL study showed that tumors were quick to answer back with a solution of their own: expression of protein PD-L1 that binds to PD-1 on the surface of T cells to prevent T cells from attacking. Thankfully, scientists have already developed antibodies that serve as checkpoint inhibitors to counter the PD-L1/PD-1 inhibition of T cells.

“Certain anti-angiogenic drugs, namely ANGPT2 inhibitors, have more profound effects on tumors than initially thought,” De Palma explained. “Besides targeting the blood vessels, they also help initiate anti-tumoral immune responses, which can be reinforced by immune checkpoint blockade.”

Based on De Palma’s findings, it seems that scientists are just unveiling the beginning of the potential benefits of applying the A2V antibody. Future studies will illustrate just how valuable this new approach will be for fighting cancer.

The present study was published in the journal Science Translational Medicine. For more on cancer immunotherapy, check out the video below: 

Sources: Ecole Polytechnique Federale De Lausanne (EPFL)

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 24, 2021
Health & Medicine
Myocarditis and COVID-19 Vaccination
AUG 24, 2021
Myocarditis and COVID-19 Vaccination
Myocarditis has been linked to sudden cardiac death in young, healthy athletes and smallpox, influenza, hepatitis B, and ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
SEP 14, 2021
Immunology
Extinguishing Fires in the Brains of MS Patients
SEP 14, 2021
Extinguishing Fires in the Brains of MS Patients
  A closer look at the brains of patients with aggressive, debilitating forms of multiple sclerosis (MS) reveals so ...
OCT 28, 2021
Cancer
NF-κB: a Trick or a Treat for Cancer?
OCT 28, 2021
NF-κB: a Trick or a Treat for Cancer?
A family of proteins, known as transcription factors, regulate the biological process of converting DNA into RNA. T ...
NOV 12, 2021
Health & Medicine
T-Cell Signature Distinguishes COVID-19 Immunity from Other Respiratory Infections
NOV 12, 2021
T-Cell Signature Distinguishes COVID-19 Immunity from Other Respiratory Infections
COVID-19 is a highly studied disease. It’s caused the most significant influx of research papers in a single year& ...
NOV 17, 2021
Health & Medicine
Nutrients for Reducing Autoimmune Disease Risk
NOV 17, 2021
Nutrients for Reducing Autoimmune Disease Risk
Want to reduce your chances of having your immune system turn on your body and start destroying your perfect health? Loo ...
Loading Comments...